Related references
Note: Only part of the references are listed.The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-Analysis
Ning Zhang et al.
CANCER INVESTIGATION (2011)
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
Marco Colleoni et al.
EUROPEAN JOURNAL OF CANCER (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)
M. Arnedos et al.
ANNALS OF ONCOLOGY (2009)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
T. Hirata et al.
BRITISH JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy
Masako Kasami et al.
BREAST (2008)
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
J. Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Evaluation of biological pathways involved in chemotherapy response in breast cancer
Attila Tordai et al.
BREAST CANCER RESEARCH (2008)
Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
Olivier Tacca et al.
ONCOLOGIST (2007)
High prognostic significance of residual disease after neoadjuvant chemotherapy:: a retrospective study in 710 patients with operable breast cancer
S Amat et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Stability of the HER2 gene after primary chemotherapy in advanced breast cancer
Z Varga et al.
VIRCHOWS ARCHIV (2005)
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
T Petit et al.
EUROPEAN JOURNAL OF CANCER (2004)
Proceedings of the Consensus Conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania
GF Schwartz et al.
CANCER (2004)
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy
S Taucher et al.
ENDOCRINE-RELATED CANCER (2003)
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
IF Faneyte et al.
BRITISH JOURNAL OF CANCER (2003)
Share Paper
